Akari Therapeutics' lead compound, nomacopan is a novel biologic therapy that inibits both the complement (C5) and leukotriene (LTB4) pathways. It is currently in phase 3 for two orphan inflammatory diseases. It is also being considered for the inhaled treatment of exacerbations across a range of lung conditions including severe asthma and COPD.

Akari Therapies have chosen Inhalation Research Services and its IPL (Isolated Perfused Lung) for its latest PK (pharmacokinetic) study. ISAB's IPL is a specially tailored version of the tool designed for aerosols generated by PreciseInhale[®]. It allows a clear understanding of how quickly an inhaled drug passes through the lung's cellular wall into the blood stream, and exactly how much is left in the lungs. Its high accuracy was key to Akari Therapeutics' decision to choose IRS.

Clive Richardson, CEO Akari Therapeutics: "We're pleased to be working with Inhalation Research Services. Their extensive experience, combined with the accuracy of this technology, inspires confidence and we believe will help us refine our inhaled treatment strategy with Nomacopan."

Manoush Masarrat, CEO Inhalation Sciences: "We are delighted to be working with this project. New biologic therapies are an exciting and thriving area of research within inhalation. Our work with Akari Therapeutics underlines how well we can support companies in this - with services like IPL and our XposeALI[® ]system, which connects the PreciseInhale[®] to measure the effect of inhaled proteins on cell layers. This is an exciting project and we're pleased to be moving ahead with it."